Dr. William Heyward on the Forefront of the Fight Against the World's Deadliest Communicable Diseases
For nearly three decades, William Heyward has been on the forefront in the fight against some of the world's deadliest communicable diseases. HIV/AIDS, Ebola, haemophilius influenzae, hepatitis B, and hepatic cancer are among the many illnesses he has focused his attention on in places as far-flung as Zaire, Alaska, South America and Thailand. Dr. Heyward has lived on the leading edge of research on the causes, effects and prevention of devastating diseases among some of the world's poorest area
Los Angeles, CA, October 12, 2007 --(PR.com)-- Dr. Heyward Joined CDC in 1979. His first post was in Anchorage, Alaska, where he worked with indigenous populations for nearly ten years. During this time he led the fights against Hepatitis B, liver cancer and haemophilus influenzae which have nearly eradicated these diseases among Alaskan natives.
In 1988, Dr. Heyward rejoined the CDC in Atlanta to form the International AIDS Program. He spearheaded epidemiological studies of HIV/AIDS in Brazil, Honduras, Zaire (now Congo), Guinea Bissau, Burkina Faso, Ivory Coast, and Thailand. Later, in collaboration with foreign ministries of health, he coordinated development of CDC field stations for the study of HIV/AIDS in Ivory Coast and Thailand. Over the next twelve years, his mission against AIDS would pair him with the World Health Organization in Zaire, Rwanda, Uganda, Thailand, and Brazil. He also helped investigate the Ebola epidemic in Zaire.
Following retirement from the CDC in 2000, Dr. Heyward was tapped V.P. for International Clinical Research with VaxGen, Inc., where he worked on trials for an HIV vaccine for Thailand, the U.S., Canada, and Europe. He also assisted the Walter Reed Army Institute for Research in developing plans for a “prime-boost” vaccination strategy with the canary pox vaccine.
Leaving VaxGen in January 2004, Dr. Heyward served as consultant to the International AIDS Vaccine Initiative and the Ministry of Health in Brazil. In April 2004, he formed Quattro Clinical Research (QCR), a Clinical Research Organization consulting with many bio-tech and pharmaceutical companies on infectious diseases, including HIV/AIDS and meningococcal vaccines, allergy vaccines, vaginal microbicides for the prevention of HIV infection in women of developing countries, and cancer compounds.
###
In 1988, Dr. Heyward rejoined the CDC in Atlanta to form the International AIDS Program. He spearheaded epidemiological studies of HIV/AIDS in Brazil, Honduras, Zaire (now Congo), Guinea Bissau, Burkina Faso, Ivory Coast, and Thailand. Later, in collaboration with foreign ministries of health, he coordinated development of CDC field stations for the study of HIV/AIDS in Ivory Coast and Thailand. Over the next twelve years, his mission against AIDS would pair him with the World Health Organization in Zaire, Rwanda, Uganda, Thailand, and Brazil. He also helped investigate the Ebola epidemic in Zaire.
Following retirement from the CDC in 2000, Dr. Heyward was tapped V.P. for International Clinical Research with VaxGen, Inc., where he worked on trials for an HIV vaccine for Thailand, the U.S., Canada, and Europe. He also assisted the Walter Reed Army Institute for Research in developing plans for a “prime-boost” vaccination strategy with the canary pox vaccine.
Leaving VaxGen in January 2004, Dr. Heyward served as consultant to the International AIDS Vaccine Initiative and the Ministry of Health in Brazil. In April 2004, he formed Quattro Clinical Research (QCR), a Clinical Research Organization consulting with many bio-tech and pharmaceutical companies on infectious diseases, including HIV/AIDS and meningococcal vaccines, allergy vaccines, vaginal microbicides for the prevention of HIV infection in women of developing countries, and cancer compounds.
###
Contact
William Heyward
415.347.4578
www.quattroclinical.com/management.htm
415.347.4578
www.quattroclinical.com/management.htm
Contact
Categories